You are here: Industry Insights > Yescarta

News List

Veklury Drives 2Q Growth for Gilead contractpharma
August 02, 2021
Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.
China's first CAR-T Cell Therapy approved-Fosun Kite Axicabtagene Ciloleucel (FKC876) prnasia
June 25, 2021
On June 23, 2021, Fosun Kite Biotechnology announced its autologous CD19-directed CAR-T cell therapy Axicabtagene Ciloleucel (FKC876) (axicabtagene ciloleucel) has been approved by China National Medical Products Administration (NMPA) for the ...
Gilead Revenues up 16% in the Quarter contractpharma
May 06, 2021
Veklury drives growth in the quarter, offsetting significant declines in HIV, HCV franchises.
Kite gets US FDA nod for Yescarta to treat relapsed or refractory follicular lymphoma expresspharma
March 08, 2021
Kite, a Gilead Company, announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two ...
Gilead’s CAR T therapy Yescarta shows potential in new indication pharmatimes
December 10, 2020
Gilead’s Yescarta has scored some promising interim results from a phase II study evaluating the chimeric antigen receptor (CAR) T therapy as a first-line treatment for high-risk large B-cell lymphoma (LBCL) patients.
Kite’s Yescarta yields positive results in ZUMA-1 trial in refractory large B-cell lymphoma pharmaceutical-business-review
December 11, 2019
Kite, a Gilead Company announced new data from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma.
Medicare proposal will increase payments for CAR-T cell therapies Yescarta, Kymriah firstwordpharma
April 25, 2019
The US Centers for Medicare and Medicaid Services (CMS) issued a proposal that would see an increase in payments for CAR-T cell therapies ...
Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah fiercepharma
December 05, 2018
Gilead and Novartis are working to ramp up launches of their slow-starting CAR-T drugs, and both companies are hoping longer-term follow-up data will help do the trick.
Gilead's CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma pharmafile
December 04, 2018
Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the latter’s reveal of data on rival Kymriah with study findings of its own CAR-T therapy Yescarta (Axicabtagene Ciloleucel).
Gilead strikes deal with NHS England on Yescarta access pharmatimes
October 11, 2018
Gilead has struck a deal with NHS England that allows some adults with lymphoma access to its “game-changing” CAR-T therapy Yescarta.

Previous page 1 2 Next page